Objectives: To evaluate the efficacy of solifenacin, tamsulosin OCAS, and combination of both drugs on double-J stent related symptoms using validated Arabic version of ureteric stent symptom questionnaire (USSQ). Patients and Method: Two hundred and sixty cases for whom double-J (DJ) stenting of the ureter was applied as part of different endoscopic urologic procedures, were postoperatively randomly assigned into four equal groups. Control (group I) received no treatment, group II tamsulosin OCAS 0.4mg daily, group III solifencin 5mg daily while group IV patients received a combination of both drugs. Before stent removal, all patients completed the Arabic version of USSQ. Results: In all, 234 cases completed the study. Control group (56 cases), group II (59 cases), group III (58 cases), and group IV (61 cases). Baseline characteristics and indications for DJ stenting were comparable in the four groups. There was highly significant difference in all items of USSQ between treatment groups versus controls, while it was comparable between group II and III. USSQ score was significantly lower in group IV versus group II and III. Crossing of the distal curl of stent to the midline had significant positive correlation with the severity of the urinary symptoms, body pain, general health, work performance in the medicated groups. Conclusion: Combined therapy with tamsulosin OCAS 0.4 mg daily and solifenacin 5 mg daily is a safe and well-tolerated management for stent-related symptoms. However, stent position stills a significant factor affecting response to medical therapy and patients' QoL